AveXis (AVXS) PT Raised to $80 at BMO Capital Following AVXS-101 Update

November 2, 2016 6:28 AM EDT
Get Alerts AVXS Hot Sheet
Price: $52.66 -1.46%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 16 | Down: 26 | New: 28
Trade AVXS Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

BMO Capital analyst M. Ian Somaiya raised his price target on Outperform-rated AveXis (NASDAQ: AVXS) to $80.00 (from $52.00) as they pull forward by 12 months FDA approval of AVXS-101 for type I SMA (2019), with >70% probability of launch by late-2017/early-2018 if the FDA accepts Phase I filing.

Somaiya commented, "DA’s willingness to accept a 20-patient Phase II trial for approval speaks to the strength of the Phase I data, which demonstrated improvement in outcomes and achievement of motor milestones. Our revised estimates assume more rapid adoption, higher market share and peak sales >$1B in the US and EU alone."

For an analyst ratings summary and ratings history on AveXis click here. For more ratings news on AveXis click here.

Shares of AveXis closed at $48.01 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change, FDA, Hot Comments

Related Entities

BMO Capital, S1

Add Your Comment